



Feidhmeannacht na Seirbhíse Sláinte
Health Service Executive

Rannan na nOspideil Ghearmhíochaine
Aonad 4A – Áras Dargan
An Ceantar Theas
An Bothar Mileata
Cill Mhaighneann
BÁC 8

Acute Operations
Health Service Executive
Unit 4A - The Dargan Building
Heuston South Quarter
Military Road
Kilmainham
Dublin 8.

Date: 14th October 2022

Deputy Pádraig Mac Lochlainn
Dáil Éireann
Leinster House
Dublin 2.

PQ 46721/22 *To ask the Minister for Health if funding will be made available to speed up the process of genetic testing for confirmation of TTR genotype (wild-type or hereditary) for transthyretin amyloidosis patients;and if he will make a statement on the matter.*

Dear Deputy Mac Lochlainn,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question, which you submitted for response. I have examined the matter and the following outlines the position.

Response:

The development of the National Genetics and Genomics Strategy has been underway since May this year. An expert Steering Group chaired by Dr Mark Bale, former Genomics Advisor to the UK Department of Health, and including representatives from a range of clinical specialties in Ireland, academic and patient representatives, and international experts in the area of genetics and genomics is leading the development of the strategy. This work is a priority of HSE Chief Clinical Officer, Dr Colm Henry, and is led by the Strategic Programmes Office of the CCO.

The National Strategy, which will be published by the end of this year, will define what actions and resources are needed so that the HSE can develop a genomic service for Ireland that will improve health outcomes, drive down the cost of care, and fuel scientific innovation and discovery

I trust that this answers your question to your satisfaction.

Yours sincerely,

Brian Dunne
General Manager Acute Operations